Product Description
Mechanisms of Action: CDH17 Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Multitude Therapeutics Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for AMT-676](https://pryzm-maps.s3.us-west-2.amazonaws.com/8current_maps.png)
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
AMT-676-01 | P1 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
2025-10-15 |